Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Roland Seiler, Ewan A. Gibb, Natalie Q. Wang, Htoo Zarni Oo, Hung‐Ming Lam, Kim E. van Kessel, Charlotte S. Voskuilen, Brian Winters, Nicholas Erho, Mandeep Takhar, James J. Douglas, Funda Vakar‐Lopez, Simon J. Crabb, Bas W.G. van Rhijn, Elisabeth E. Fransen van de Putte, Ellen C. Zwarthoff, George N. Thalmann, Elai Davicioni, Joost L. Boormans, Marc Dall’Era, Michiel S. van der Heijden, Jonathan L. Wright, Peter C. Black
This study expands our knowledge on MIBC not responding to cisplatin by suggesting molecular subtypes to understand the biology of these tumors. Although these molecular subtypes imply consequences for adjuvant treatments, this ultimately needs to be tested in clinical trials.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.